Vogt-Koyanagi-Harada disease: Clinical outcomes

Irina Bykhovskaya, Jennifer Thorne, John H. Kempen, James P. Dunn, Douglas Jabs

Research output: Contribution to journalArticle

Abstract

• PURPOSE: To evaluate the effect of treatment on the incidence of vision impairment and structural ocular complications among patients with Vogt-Koyanagi-Harada (VKH) disease. • DESIGN: Retrospective cohort study. • METHODS: setting: Single-center academic practice. study population: Twenty-four consecutive patients with VKH disease who were referred for evaluation and treatment from November 1984 through May 2004. procedures: Information on patients with VKH disease was entered retrospectively into a database and analyzed with time-dependent techniques. main outcome measures: Incidence of visual impairment and of structural ocular complications. • RESULTS: In better-seeing eyes, the frequencies of vision loss to 20/50 or worse and to 20/200 or worse at presentation were 50% and 30%, respectively. The incidence rates on follow-up examination for vision loss to 20/50 or worse and to 20/200 or worse were 9% per person-year and 7% per person-year in the better-seeing eye. Oral corticosteroid therapy was associated with a reduced risk of loss of visual acuity to the 20/200 or worse in the better-seeing eye (relative risk [RR] = 0.33; P = .05). The use of immunosuppressive drug therapy was associated with a reduced risk of vision loss to the 20/50 or worse and to the 20/200 or worse thresholds in the better-seeing eye (RR = 0.33; P = .05; and RR = 0.08; P = .04, respectively). • CONCLUSION: VKH disease may result in substantial visual impairment. The use of oral corticosteroid or immunosuppressive drug therapy may reduce the risk of vision loss during the follow-up period.

Original languageEnglish (US)
JournalAmerican Journal of Ophthalmology
Volume140
Issue number4
DOIs
StatePublished - Oct 2005

Fingerprint

Uveomeningoencephalitic Syndrome
Vision Disorders
Immunosuppressive Agents
Incidence
Adrenal Cortex Hormones
Drug Therapy
Low Vision
Visual Acuity
Cohort Studies
Therapeutics
Retrospective Studies
Outcome Assessment (Health Care)
Databases
Population

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Vogt-Koyanagi-Harada disease : Clinical outcomes. / Bykhovskaya, Irina; Thorne, Jennifer; Kempen, John H.; Dunn, James P.; Jabs, Douglas.

In: American Journal of Ophthalmology, Vol. 140, No. 4, 10.2005.

Research output: Contribution to journalArticle

Bykhovskaya, Irina ; Thorne, Jennifer ; Kempen, John H. ; Dunn, James P. ; Jabs, Douglas. / Vogt-Koyanagi-Harada disease : Clinical outcomes. In: American Journal of Ophthalmology. 2005 ; Vol. 140, No. 4.
@article{efe7cba3af234702b14bba5e065a1747,
title = "Vogt-Koyanagi-Harada disease: Clinical outcomes",
abstract = "• PURPOSE: To evaluate the effect of treatment on the incidence of vision impairment and structural ocular complications among patients with Vogt-Koyanagi-Harada (VKH) disease. • DESIGN: Retrospective cohort study. • METHODS: setting: Single-center academic practice. study population: Twenty-four consecutive patients with VKH disease who were referred for evaluation and treatment from November 1984 through May 2004. procedures: Information on patients with VKH disease was entered retrospectively into a database and analyzed with time-dependent techniques. main outcome measures: Incidence of visual impairment and of structural ocular complications. • RESULTS: In better-seeing eyes, the frequencies of vision loss to 20/50 or worse and to 20/200 or worse at presentation were 50{\%} and 30{\%}, respectively. The incidence rates on follow-up examination for vision loss to 20/50 or worse and to 20/200 or worse were 9{\%} per person-year and 7{\%} per person-year in the better-seeing eye. Oral corticosteroid therapy was associated with a reduced risk of loss of visual acuity to the 20/200 or worse in the better-seeing eye (relative risk [RR] = 0.33; P = .05). The use of immunosuppressive drug therapy was associated with a reduced risk of vision loss to the 20/50 or worse and to the 20/200 or worse thresholds in the better-seeing eye (RR = 0.33; P = .05; and RR = 0.08; P = .04, respectively). • CONCLUSION: VKH disease may result in substantial visual impairment. The use of oral corticosteroid or immunosuppressive drug therapy may reduce the risk of vision loss during the follow-up period.",
author = "Irina Bykhovskaya and Jennifer Thorne and Kempen, {John H.} and Dunn, {James P.} and Douglas Jabs",
year = "2005",
month = "10",
doi = "10.1016/j.ajo.2005.04.052",
language = "English (US)",
volume = "140",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Vogt-Koyanagi-Harada disease

T2 - Clinical outcomes

AU - Bykhovskaya, Irina

AU - Thorne, Jennifer

AU - Kempen, John H.

AU - Dunn, James P.

AU - Jabs, Douglas

PY - 2005/10

Y1 - 2005/10

N2 - • PURPOSE: To evaluate the effect of treatment on the incidence of vision impairment and structural ocular complications among patients with Vogt-Koyanagi-Harada (VKH) disease. • DESIGN: Retrospective cohort study. • METHODS: setting: Single-center academic practice. study population: Twenty-four consecutive patients with VKH disease who were referred for evaluation and treatment from November 1984 through May 2004. procedures: Information on patients with VKH disease was entered retrospectively into a database and analyzed with time-dependent techniques. main outcome measures: Incidence of visual impairment and of structural ocular complications. • RESULTS: In better-seeing eyes, the frequencies of vision loss to 20/50 or worse and to 20/200 or worse at presentation were 50% and 30%, respectively. The incidence rates on follow-up examination for vision loss to 20/50 or worse and to 20/200 or worse were 9% per person-year and 7% per person-year in the better-seeing eye. Oral corticosteroid therapy was associated with a reduced risk of loss of visual acuity to the 20/200 or worse in the better-seeing eye (relative risk [RR] = 0.33; P = .05). The use of immunosuppressive drug therapy was associated with a reduced risk of vision loss to the 20/50 or worse and to the 20/200 or worse thresholds in the better-seeing eye (RR = 0.33; P = .05; and RR = 0.08; P = .04, respectively). • CONCLUSION: VKH disease may result in substantial visual impairment. The use of oral corticosteroid or immunosuppressive drug therapy may reduce the risk of vision loss during the follow-up period.

AB - • PURPOSE: To evaluate the effect of treatment on the incidence of vision impairment and structural ocular complications among patients with Vogt-Koyanagi-Harada (VKH) disease. • DESIGN: Retrospective cohort study. • METHODS: setting: Single-center academic practice. study population: Twenty-four consecutive patients with VKH disease who were referred for evaluation and treatment from November 1984 through May 2004. procedures: Information on patients with VKH disease was entered retrospectively into a database and analyzed with time-dependent techniques. main outcome measures: Incidence of visual impairment and of structural ocular complications. • RESULTS: In better-seeing eyes, the frequencies of vision loss to 20/50 or worse and to 20/200 or worse at presentation were 50% and 30%, respectively. The incidence rates on follow-up examination for vision loss to 20/50 or worse and to 20/200 or worse were 9% per person-year and 7% per person-year in the better-seeing eye. Oral corticosteroid therapy was associated with a reduced risk of loss of visual acuity to the 20/200 or worse in the better-seeing eye (relative risk [RR] = 0.33; P = .05). The use of immunosuppressive drug therapy was associated with a reduced risk of vision loss to the 20/50 or worse and to the 20/200 or worse thresholds in the better-seeing eye (RR = 0.33; P = .05; and RR = 0.08; P = .04, respectively). • CONCLUSION: VKH disease may result in substantial visual impairment. The use of oral corticosteroid or immunosuppressive drug therapy may reduce the risk of vision loss during the follow-up period.

UR - http://www.scopus.com/inward/record.url?scp=26844466276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844466276&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2005.04.052

DO - 10.1016/j.ajo.2005.04.052

M3 - Article

C2 - 16226518

AN - SCOPUS:26844466276

VL - 140

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 4

ER -